These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Laboratory assessment of the anticoagulant activity of dabigatran.
    Author: Kyriakou E, Ikonomidis I, Stylos D, Bonovas S, Papadakis I, Nikolopoulos GK, Kokoris S, Kalantzis D, Economopoulou C, Kopterides P, Lekakis J, Tsantes AE.
    Journal: Clin Appl Thromb Hemost; 2015 Jul; 21(5):434-45. PubMed ID: 25525048.
    Abstract:
    BACKGROUND: Our aim was to identify laboratory assays in order to assess the anticoagulant effects of dabigatran etexilate (DE). METHODS: Twenty patients with nonvalvular atrial fibrillation treated on DE (110 mg per os twice daily) and 20 on acenocoumarol were studied. Conventional coagulation tests, endogenous thrombin potential (ETP), thromboelastometry (ROTEM), epinephrine-induced light transmission aggregometry (LTA), and Hemoclot Thrombin Inhibitors (HTI) were performed in all patients. RESULTS: In ROTEM analysis, the lysis index at 60 minutes was significantly lower in patients receiving DE (P = .011). In LTA, patients on DE showed decreased aggregation compared to those on acenocoumarol, marginally insignificant (P = .068). Regarding ETP, acenocoumarol affected thrombin generation more than dabigatran (area under the curve [AUC], P < .001), while statistically significant associations were detected between dabigatran levels, as determined by the HTI assay, and almost all parameters of ETP assay (AUC, P < .001). CONCLUSION: The role of ETP in estimating anticoagulant activity of dabigatran possibly requires further research.
    [Abstract] [Full Text] [Related] [New Search]